Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Viva Biotech reported 1H26 revenue of RMB1,006.5m (+21.0% YoY) and gross profit of RMB341.7m (+0.7% YoY), with gross margin stable at 34.0%, supported by Langhua Pharmaceutical’s CDMO ramp (one peptide in commercial stockpiling and one small-molecule in PPQ). However, net profit fell to RMB100.9m and adjusted non-IFRS net profit declined to RMB128.3m, mainly due to lower investment income, FX headwinds, and higher R&D spending. On the CRO side, AI-led demand is rising: revenue was RMB405.1m, AI-empowered projects contributed ~14.0% of CRO revenue, and new modality offerings grew ~10.7% YoY. Overall, results show strong top-line momentum offset by profitability pressure, with an expectation to sustain full-year 2026 growth at or above current levels.

Analysis

The key takeaway is not the top-line growth; it is the mix shift toward commercially validated work. That usually improves backlog quality and lowers revenue volatility, but it also tends to cap multiple expansion because investors pay up for platform optionality only when it converts into recurring, high-ROIC cash flow rather than project wins.

On the competitive side, integrated CRO/CDMO players with peptide, oligo, and small-molecule handoff capabilities are the likely winners because clients increasingly want fewer transfer points between design, CMC, and commercial supply. Pure-play discovery shops without manufacturing adjacency could lose share at the margin if procurement teams favor one-stop vendors, while the capacity buildout implies a second-order risk: as industry supply catches up, pricing power in non-differentiated CDMO work should normalize over 6-18 months.

Near term, the stock is likely to trade on whether the second half proves that margin dilution from new-business R&D and FX is temporary. The real falsifier is not the AI narrative; it is whether paid AI-driven projects, client concentration, and gross margin can hold while new capacity gets utilized. If 2H margin slips below the low-30s or conversion from PPQ to commercial production stalls, the market will likely re-rate this as a capital-intensive services business rather than an AI compounder.

Key Decisions for Investors

• No high-conviction directional trade in VBIZF today; treat the print as a confirmatory update, not a catalyst. Reassess only if 2H gross margin and cash conversion improve while the new capacity ramps.
• If the stock sells off 3-5% on the weaker net income line, consider a tactical long in VBIZF for a 1-3 month rebound trade, but only with a hard stop if management signals margin compression or delayed commercialization conversion.
• Relative-value watch: long integrated CRO/CDMO exposure over pure AI-drug-discovery names if you want monetized demand rather than narrative optionality. The better trade is the business with actual client-funded wet lab work, not the one selling platform promises.
• Set an alert for gross margin below 32% or for any slowdown in commercial project conversion over the next 1-2 quarters; that would invalidate the thesis that growth is becoming higher quality rather than just larger.